ScPharmaceuticals (SCPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Preliminary unaudited fourth quarter 2024 net revenue expected to be approximately $12 million to $12.3 million, representing 99% growth over Q4 2023 at the mid-point of the range
scPharmaceuticals Inc. (NASDAQ:SCPH ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Nick Colangelo - Investor Relations John Tucker - Chief Executive Officer Steve Parsons - Senior Vice President of Commercial Rachael Nokes - Chief Financial Officer Conference Call Participants Anupam Leesy - Leerink Partners Stacy Ku - TD Cowen Douglas Tsao - H.C. Wainwright Chase Knickerbocker - Craig-Hallum Operator Good afternoon, and welcome to scPharmaceuticals' Third Quarter 2024 Earnings Conference Call.
ScPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.41 per share a year ago.
The mean of analysts' price targets for scPharmaceuticals (SCPH) points to a 291.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
scPharmaceuticals Inc. (NASDAQ:SCPH ) Q2 2024 Earnings Call Transcript August 14, 2024 4:30 PM ET Company Participants PJ Kelleher - IR John Tucker - CEO Steve Parsons - SVP, Commercial Rachael Nokes - CFO Conference Call Participants Roanna Ruiz - Leerink Partners Chase Knickerbocker - Craig-Hallum Capital Group Operator Greetings, and welcome to the scPharmaceuticals Second Quarter 2024 Earnings Conference Call. At this time all participants are in a listen-only mode.
ScPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.44 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.36 per share a year ago.
BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock at a public offering price of $4.00 per share and, to select investors, in lieu of common stock, pre-funded warrants to purchase up to 500,000 shares of common stock at a purchase price of $3.999 per underlying share, for gross proceeds of approximately $50.0 million, before deducting underwriting discounts and commissions and other offering expenses and excluding the exercise of the pre-funded warrants. The pre-funded warrants have an exercise price of $0.001 per share. All of the shares and the pre-funded warrants are being offered by scPharmaceuticals. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of common stock from the Company at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on August 13, 2024, subject to the satisfaction of customary closing conditions.
scPharmaceuticals received $75 million through a combination of debt and royalty financings at close, with access to an additional $50 million
FUROSCIX is now indicated for the treatment of congestion due to fluid overload in adult patients with chronic heart failure, regardless of New York Heart Association (NYHA) functional class